teaser
Boehringer Ingelheim continued to grow in 2009, increasing its net sales by 9.7% to EUR 12.7 billion (2008: EUR 11.6 billion).
This was announced today by the company at its Annual Press Conference. Even without taking into account positive currency effects, growth was once again above the average growth for the worldwide pharmaceutical market, at 6.7%. This means that for the tenth consecutive time Boehringer Ingelheim grew faster than the pharmaceutical market and in 2009 was the fastest growing company of the world’s 15 largest pharmaceutical companies.
Operating income, comparable to EBIT, rose to EUR 2.2 billion, despite higher investments planned for research and development.
Professor Andreas Barner, Chairman of the Board of Managing Directors and responsible for the Corporate Board Division Research & Development and Medicine, expressed his satisfaction with the 2009 business year: “In view of the difficult economic environment, we believe that the success of 2009 confirms that our entrepreneurial approach was right. The success of our innovative medicines for patients and our promising research pipeline give us cause to be optimistic about the future.”
Boehringer Ingelheim again invested considerably in its future in 2009, the 125th year in the company’s history. Expenditure for the research and development of new medicines and therapies again increased by more than EUR 100 million to EUR 2.2 billion. The company thus directly reinvested 21% of net sales from the Prescription Medicines business in research and development.
“Five therapeutically promising, innovative medicines from our own pipeline have provided very positive data in clinical studies,” continued Prof. Barner. “These new medicines in indication areas, some of which are new for our company, will offer patients significant therapeutic progress as well as being important for the future of Boehringer Ingelheim, which is now in its 125th year as an independent, family-owned company.”
For more information, please click the link below:
